# CYP2C9

## Overview
CYP2C9 is a gene that encodes the enzyme cytochrome P450 family 2 subfamily C member 9, a crucial component of the cytochrome P450 superfamily. This enzyme is primarily expressed in the liver and plays a significant role in the oxidative metabolism of a wide array of drugs and endogenous compounds. As a member of the cytochrome P450 family, CYP2C9 functions as a monooxygenase, facilitating the hydroxylation of substrates, which is essential for their metabolic clearance and therapeutic efficacy (Daly2017Pharmacogenomics; Miners1998Cytochrome). The enzyme's activity is subject to genetic polymorphisms, which can lead to variability in drug metabolism and necessitate personalized medication dosing (Zhou2010Polymorphisms). Additionally, CYP2C9 is involved in the metabolism of endogenous compounds such as arachidonic acid, contributing to cardiovascular health (Daly2017Pharmacogenomics). Understanding the structure, function, and interactions of CYP2C9 is critical for optimizing drug therapy and managing potential adverse effects.

## Structure
The CYP2C9 protein is a member of the cytochrome P450 superfamily, characterized by a conserved structural core that includes a four-helix bundle and a heme group bound between helices (Denisov2005Structure). The primary structure of CYP2C9 consists of a sequence of amino acids that form specific domains and motifs crucial for its function. The secondary structure includes alpha-helices and beta-sheets, with the B-C loop forming helix B0 and the F-G loop forming helices F0 and G0, a unique feature among CYP450 structures (Williams2003Crystal).

The tertiary structure of CYP2C9 is a compact, globular shape with a heme-binding domain. The heme group is located between helices I and L, with the iron pentacoordinated to Cys 435, and is stabilized by hydrogen bonds with residues such as Trp 120, Arg 124, His 368, and Arg 433 (Williams2003Crystal). The quaternary structure involves potential interactions with other proteins, although specific details are not provided in the context.

CYP2C9 also features substrate recognition sites (SRS) that play a key role in substrate binding and specificity. The active site is a large hydrophobic pocket, which can accommodate multiple ligands, suggesting an allosteric mechanism (Williams2003Crystal). Common post-translational modifications include phosphorylation and glycosylation, although specific details are not provided in the context.

## Function
The CYP2C9 gene encodes the cytochrome P450 2C9 enzyme, a critical component in the oxidative metabolism of various drugs and endogenous compounds in humans. This enzyme is part of the cytochrome P450 superfamily, which functions as terminal oxidases in the mixed function oxidase system. CYP2C9 is primarily active in the liver, where it is one of the most abundant cytochrome P450 isoforms, accounting for about 20% of the total hepatic P450 protein (Daly2017Pharmacogenomics; Miners1998Cytochrome).

CYP2C9 plays a significant role in the metabolism of a wide range of drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants like warfarin, and antiepileptic drugs such as phenytoin. It is responsible for the hydroxylation of these compounds, a process crucial for their metabolic clearance and therapeutic efficacy (Zhou2010Polymorphisms; Miners1998Cytochrome). The enzyme's activity is influenced by genetic polymorphisms, which can lead to variability in drug metabolism and necessitate individualized drug dosing (Zhou2010Polymorphisms).

CYP2C9 is also involved in the metabolism of endogenous compounds, such as arachidonic acid, contributing to the formation of epoxyeicosatrienoic acids (EETs), which have implications for cardiovascular health (Daly2017Pharmacogenomics). The enzyme's function is critical in maintaining drug plasma concentrations and ensuring effective therapeutic outcomes.

## Clinical Significance
Mutations in the CYP2C9 gene can significantly impact drug metabolism, leading to various clinical implications. The CYP2C9*2 and *3 alleles are associated with reduced drug clearance, affecting the dosing and risk of adverse effects for medications like warfarin, phenytoin, and NSAIDs. Individuals with these alleles often require lower doses of warfarin and phenytoin to avoid bleeding and neurotoxicity, respectively (Daly2017Pharmacogenomics; Jarrar2014Molecular). The CYP2C9*3/*3 genotype is linked to decreased clearance of meloxicam, increasing the risk of adverse effects (Jarrar2014Molecular).

CYP2C9 polymorphisms also influence disease susceptibility. The CYP2C9*2 and *3 alleles are associated with an increased risk of cardiovascular disease, potentially due to decreased synthesis of protective metabolites (Jarrar2014Molecular). These alleles are also more prevalent in patients with oral squamous cell carcinoma, suggesting a role in carcinogen metabolism (R2020CYP2). Additionally, CYP2C9 variations may contribute to atherosclerosis risk, particularly in smokers, due to altered metabolism of arachidonic acid and reduced synthesis of endothelium-derived hyperpolarizing factors (Ercan2007Role). The CYP2C9*3 allele is more frequent in patients with major depression, indicating a possible link to altered arachidonic acid metabolism (Jarrar2014Molecular).

## Interactions
CYP2C9 interacts with various cytochrome P450 enzymes, influencing its activity and substrate binding. It forms heteromeric complexes with CYP3A4, which significantly inhibit CYP2C9 activity, particularly in the metabolism of S-naproxen and S-flurbiprofen. This inhibition is dependent on the presence of the hydrophobic N terminus, as truncation of this region abolishes the effect (Subramanian2010CYP2C9CYP3A4; Kandel2014Role). CYP3A4 can inhibit CYP2C9 by up to 84%, with the degree of inhibition being protein dose-dependent (Subramanian2010CYP2C9CYP3A4).

CYP2C9 also interacts with CYP2D6, which can inhibit its metabolism of S-flurbiprofen by increasing the dissociation constant for substrate binding, suggesting a destabilization of the enzyme-substrate complex (Subramanian2009CYP2D6CYP2C9; Reed2016The). The interaction with CYP2C19 can stimulate CYP2C9-mediated metabolism of diclofenac, potentially by increasing the binding affinity for cytochrome P450 reductase (CPR) (Reed2016The; Reed2017Physical).

CYP2C9's interactions are not limited to other P450 enzymes. It also interacts with the progesterone receptor membrane component 1 (PGRMC1), which generally reduces CYP2C9 activity by decreasing V_max values (Kandel2014Role). These interactions highlight the complex regulatory mechanisms affecting CYP2C9's role in drug metabolism.


## References


[1. (Reed2017Physical) James R. Reed and Wayne L. Backes. Physical studies of p450–p450 interactions: predicting quaternary structures of p450 complexes in membranes from their x-ray crystal structures. Frontiers in Pharmacology, January 2017. URL: http://dx.doi.org/10.3389/fphar.2017.00028, doi:10.3389/fphar.2017.00028. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2017.00028)

[2. (Jarrar2014Molecular) Yazun Bashir Jarrar and Su-Jun Lee. Molecular functionality of cyp2c9 polymorphisms and their influence on drug therapy. Drug Metabolism and Drug Interactions, 29(4):211–220, May 2014. URL: http://dx.doi.org/10.1515/dmdi-2014-0001, doi:10.1515/dmdi-2014-0001. This article has 21 citations.](https://doi.org/10.1515/dmdi-2014-0001)

[3. (Subramanian2009CYP2D6CYP2C9) Murali Subramanian, Michael Low, Charles W. Locuson, and Timothy S. Tracy. Cyp2d6-cyp2c9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metabolism and Disposition, 37(8):1682–1689, May 2009. URL: http://dx.doi.org/10.1124/dmd.109.026500, doi:10.1124/dmd.109.026500. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/dmd.109.026500)

[4. (Daly2017Pharmacogenomics) Ann Daly, Allan Rettie, Douglas Fowler, and John Miners. Pharmacogenomics of cyp2c9: functional and clinical considerations. Journal of Personalized Medicine, 8(1):1, December 2017. URL: http://dx.doi.org/10.3390/jpm8010001, doi:10.3390/jpm8010001. This article has 140 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/jpm8010001)

[5. (Zhou2010Polymorphisms) Shu-Feng Zhou, Zhi-Wei Zhou, and Min Huang. Polymorphisms of human cytochrome p450 2c9 and the functional relevance. Toxicology, 278(2):165–188, December 2010. URL: http://dx.doi.org/10.1016/j.tox.2009.08.013, doi:10.1016/j.tox.2009.08.013. This article has 93 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.tox.2009.08.013)

[6. (Miners1998Cytochrome) John O. Miners and Donald J. Birkett. Cytochrome p4502c9: an enzyme of major importance in human drug metabolism. British Journal of Clinical Pharmacology, 45(6):525–538, June 1998. URL: http://dx.doi.org/10.1046/j.1365-2125.1998.00721.x, doi:10.1046/j.1365-2125.1998.00721.x. This article has 602 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1046/j.1365-2125.1998.00721.x)

[7. (Denisov2005Structure) Ilia G. Denisov, Thomas M. Makris, Stephen G. Sligar, and Ilme Schlichting. Structure and chemistry of cytochrome p450. Chemical Reviews, 105(6):2253–2278, April 2005. URL: http://dx.doi.org/10.1021/cr0307143, doi:10.1021/cr0307143. This article has 1744 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/cr0307143)

[8. (Subramanian2010CYP2C9CYP3A4) Murali Subramanian, Harrison Tam, Helen Zheng, and Timothy S. Tracy. Cyp2c9-cyp3a4 protein-protein interactions: role of the hydrophobic n terminus. Drug Metabolism and Disposition, 38(6):1003–1009, March 2010. URL: http://dx.doi.org/10.1124/dmd.109.030155, doi:10.1124/dmd.109.030155. This article has 50 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/dmd.109.030155)

[9. (Reed2016The) James R. Reed and Wayne L. Backes. The functional effects of physical interactions involving cytochromes p450: putative mechanisms of action and the extent of these effects in biological membranes. Drug Metabolism Reviews, 48(3):453–469, July 2016. URL: http://dx.doi.org/10.1080/03602532.2016.1221961, doi:10.1080/03602532.2016.1221961. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/03602532.2016.1221961)

[10. (Ercan2007Role) B. Ercan, L. Ayaz, D. Çiçek, and L. Tamer. Role of cyp2c9 and cyp2c19 polymorphisms in patients with atherosclerosis. Cell Biochemistry and Function, 26(3):309–313, September 2007. URL: http://dx.doi.org/10.1002/cbf.1437, doi:10.1002/cbf.1437. This article has 34 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cbf.1437)

[11. (Williams2003Crystal) Pamela A. Williams, Jose Cosme, Alison Ward, Hayley C. Angove, Dijana Matak Vinković, and Harren Jhoti. Crystal structure of human cytochrome p450 2c9 with bound warfarin. Nature, 424(6947):464–468, July 2003. URL: http://dx.doi.org/10.1038/nature01862, doi:10.1038/nature01862. This article has 682 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature01862)

[12. (Kandel2014Role) Sylvie E. Kandel and Jed N. Lampe. Role of protein–protein interactions in cytochrome p450-mediated drug metabolism and toxicity. Chemical Research in Toxicology, 27(9):1474–1486, August 2014. URL: http://dx.doi.org/10.1021/tx500203s, doi:10.1021/tx500203s. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/tx500203s)

[13. (R2020CYP2) Hannah R, Pratibha Ramani, Arvind Ramanathan, Jancy Merlin R, Gheena S, Abilasha Ramasubramanian, and Monika K. Cyp2 c9 polymorphism among patients with oral squamous cell carcinoma and its role in altering the metabolism of benzo[a]pyrene. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 130(3):306–312, September 2020. URL: http://dx.doi.org/10.1016/j.oooo.2020.06.021, doi:10.1016/j.oooo.2020.06.021. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.oooo.2020.06.021)